Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genetic Services Laboratory, |
RCV000504391 | SCV000597280 | uncertain significance | not specified | 2016-06-02 | criteria provided, single submitter | clinical testing | |
Clinical Molecular Genetics Laboratory, |
RCV000678852 | SCV000805043 | uncertain significance | Epilepsy due to perinatal stroke | 2017-06-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001857172 | SCV002201956 | uncertain significance | Early infantile epileptic encephalopathy with suppression bursts | 2022-06-20 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. ClinVar contains an entry for this variant (Variation ID: 436873). This variant has not been reported in the literature in individuals affected with ST3GAL3-related conditions. This variant is present in population databases (rs745451424, gnomAD 0.003%). This sequence change replaces asparagine, which is neutral and polar, with serine, which is neutral and polar, at codon 134 of the ST3GAL3 protein (p.Asn134Ser). |
Revvity Omics, |
RCV003139706 | SCV003825833 | uncertain significance | not provided | 2019-11-25 | criteria provided, single submitter | clinical testing |